Citations

Showing 10 of 108135 citations.

Local Pro- and Anti-Coagulation Therapy in the Plastic Surgical Patient: A Literature Review of the Evidence and Clinical Applications
Oliver, Jeremie D. , DeLoughery, Emma P. , Sisti, Andrea , Huayllani, María T. , Restrepo, David J. , Hu, Michael S. , Forte, Antonio J. , Boczar, Daniel , Sisti, Andrea , Huayllani, Maria T , Forte, Antonio Jorge , Oliver, Jeremie D , Gupta, Nikita

Mayo Clinic

Medicina | May 24, 2019 | Volume: 55 | Issue: 5 | Pages: 208

10.3390/medicina55050208 | PMID 31137735 Get It

The risks of systemic anti-coagulation or its reversal are well known but accepted as necessary under certain circumstances. However, particularly in the plastic surgical patient, systemic alteration to hemostasis is often unnecessary when local therapy could provide the needed adjustments. The aim of this review was to provide a summarized overview of the clinical applications of topical anti- and pro-coagulant therapy in plastic and reconstructive surgery. While not a robust field as of yet, local tranexamic acid (TXA) has shown promise in achieving hemostasis under various circumstances, hemostats are widely used to halt bleeding, and local anticoagulants such as heparin can improve flap survival. The main challenge to the advancement of local therapy is drug delivery. However, with increasingly promising innovations underway, the field will hopefully expand to the betterment of patient care.
Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma
Jakubowiak, Andrzej , Jasielec, Jagoda, Rosenbaum, Cara A. , Cole, Craig E. , Chari, Ajai , Nam, Jennifer, McIver, Amanda, Severson, Erica, Stephens, Leonor A, Tinari, Kathryn M., Rosebeck, Shaun , Zimmerman, Todd M., Hycner, Tyler, Turowski, Agata, Karrison, Theodore, Zonder, Jeffrey A. , Jakubowiak, Andrzej J , Mıkhael, Joseph , Zonder, Jeffrey A , Chari, Ajai

Mayo Clinic

British Journal of Haematology | May 24, 2019 | Volume: 186 | Issue: 4 | Pages: 549-560

10.1111/bjh.15969 | PMID 31124580 Get It

SummarySelinexor, an oral Selective Inhibitor of Nuclear Export, targets Exportin 1 (XPO1, also termed CRM1). Non‐clinical studies support combining selinexor with proteasome inhibitors (PIs) and corticosteroids to overcome resistance in relapsed/refractory multiple myeloma (RRMM). We conducted a phase I dose‐escalation trial of twice‐weekly selinexor in combination with carfilzomib and dexamethasone (SKd) to determine maximum tolerated dose in patients with RRMM (N = 21), with an expansion cohort to assess activity in carfilzomib‐refractory disease and identify a recommended phase II dose (RP2D). During dose escalation, there was one dose‐limiting toxicity (cardiac failure). The RP2D of twice‐weekly SKd was selinexor 60 mg, carfilzomib 20/27 mg/m2 and dexamethasone 20 mg. The most common grade 3/4 treatment‐emergent adverse events included thrombocytopenia (71%), anaemia (33%), lymphopenia (33%), neutropenia (33%) and infections (24%). Rates of ≥minimal response, ≥partial response and very good partial response were 71%, 48% and 14%, respectively; similar response outcomes were observed for dual‐class refractory (PI and immunomodulatory drug)/quad‐exposed (carfilzomib, bortezomib, lenalidomide and pomalidomide) patients (n = 17), and patients refractory to carfilzomib in last line of therapy (n = 13). Median progression‐free survival was 3·7 months, and overall survival was 22·4 months in the overall population. SKd was tolerable and re‐established disease control in RRMM patients, including carfilzomib‐refractory patients.Registered at ClinicalTrials.gov (NCT02199665)
Outcomes of Patients With Severe Symptomatic Aortic Valve Stenosis After Chest Radiation: Transcatheter Versus Surgical Aortic Valve Replacement
Zhang, Dongfeng , Guo, Wei , Al‐Hijji, Mohammed , Sabbagh, Abdallah El , Lewis, Bradley R., Greason, Kevin L. , Sandhu, Gurpreet S. , Eleid, Mackram F. , Holmes, David R. , Herrmann, Joerg , Al-Hijji, Mohammed A , Greason, Kevin

Mayo Clinic

Journal of the American Heart Association | May 24, 2019 | Volume: 8 | Issue: 10 | Pages: No page available

10.1161/jaha.119.012110 | PMID 31124737 Get It

Background Patients with symptomatic severe aortic stenosis and a history of chest radiation therapy represent a complex and challenging cohort. It is unknown how transcatheter aortic valve replacement ( TAVR ) compares with surgical aortic valve replacement in this group of patients, which was the objective of this study. Methods and Results We retrospectively reviewed all patients with severe aortic stenosis who underwent either TAVR or surgical aortic valve replacement at our institution with a history of mediastinal radiation (n=55 per group). End points were echocardiographic and clinical outcomes in‐hospital, at 30 days, and at 1 year. Inverse propensity weighting analysis was used to account for intergroup baseline differences. TAVR patients had a higher STS score than surgical aortic valve replacement patients (5.1% [3.2, 7.7] versus 1.6% [0.8, 2.6], P <0.001) and more often ( P <0.01 for all) a history of atrial fibrillation (45.5% versus 12.7%), chronic lung disease (47.3% versus 7.3%), peripheral arterial disease (38.2% versus 7.3%), heart failure (58.2% versus 18.2%), and pacemaker therapy (23.6% versus 1.8%). Postoperative atrial fibrillation was less frequent (1.8% versus 27.3%; P <0.001) and hospital stay was shorter in TAVR patients (4.0 [2.0, 5.0] versus 6.0 [5.0, 8.0] days; P <0.001). The ratio of observed‐to‐expected 30‐day mortality was lower after TAVR as was 30‐day mortality in inverse propensity weighting–adjusted Kaplan–Meier analyses. Conclusions In patients with severe aortic stenosis and a history of chest radiation therapy, TAVR performs better than predicted along with less adjusted 30‐day all‐cause mortality, postoperative atrial fibrillation, and shorter hospitalization compared with surgical aortic valve replacement. These data support further studies on the preferred role of TAVR in this unique patient population.
Adolescent male fertility following reduced‐intensity conditioning regimen for hematopoietic stem cell transplantation in non‐malignant disorders
Zhao, Jun , Beebe, Kristen , Magee, Kyrie, Salzberg, Dana, Stahlecker, Jennifer, Miller, Holly, Adams, Roberta H. , Lipskind, S.T., Walsh, Alexandra , Mirea, Lucia , Ngwube, Alexander

Mayo Clinic

Pediatric Transplantation | May 24, 2019 | Volume: 23 | Issue: 6 | Pages: No page available

10.1111/petr.13496 | PMID 31124253 Get It

AbstractIntroductionThe effects of RIC for HSCT on male fertility remain unknown. We investigated spermatogenesis and gonadal hormonal status among adolescent male patients who received RIC HSCT for non‐malignant diseases.Patients and MethodsPatients with non‐malignant disease who had undergone a RIC HSCT were recruited and evaluated for spermatogenesis via semen analysis and gonadal hormonal function via serum hormone levels. Those who had received prior chemotherapy or radiation were excluded from the study. We reviewed the charts to record demographic factors, conditioning regimen and complications during and after transplant.ResultsFive patients were enrolled. The median age at the time of transplant was 15 years (range, 11‐19 years), and the median time between bone marrow transplant and semen analysis was 5 years (range, 3‐11 years). Median age of patients was 20 years (range, 18‐25 years) at the time of the study. Serum FSH and LH levels were elevated in four patients, and inhibin B levels were low for age in three patients. Semen analysis showed two patients had azoospermia, and the remaining three patients showed severe oligozoospermia. Normal morphology and motility were seen in only one patient.ConclusionThis case series suggests that RIC transplants may be associated with impaired spermatogenesis and sequential follow‐up is necessary given the potential for either permanent impairment or delayed recovery. Further larger studies are needed to confirm these findings.
Magnetic Resonance Elastography of Liver in Light Chain Amyloidosis
Venkatesh, Sudhakar K. , Hoodeshenas, Safa, Venkatesh, Sandeep H., Dispenzieri, Angela, Gertz, Morie A. , Torbenson, Michael S., Ehman, Richard L., Gertz, Morie A , Venkatesh, Sudhakar K , Hoodeshenas, Safa , Venkatesh, Sandeep Halagatti, Dispenzieri, Angela , Torbenson, Michael S., Ehman, Richard L.

Mayo Clinic

Journal of Clinical Medicine | May 24, 2019 | Volume: 8 | Issue: 5 | Pages: 739

10.3390/jcm8050739 | PMID 31126105 Get It

In this paper, we present our preliminary findings regarding magnetic resonance elastography (MRE) on the livers of 10 patients with systemic amyloidosis. Mean liver stiffness measurements (LSM) and spleen stiffness measurements (SSM) were obtained. Magnetic resonance imaging (MRI) images were analyzed for the distribution pattern of amyloid deposition. Pearson correlation analysis was performed in order to study the correlation between LSM, SSM, liver span, liver volume, spleen span, spleen volume, serum alkaline phosphatase (ALP), N-terminal pro b-type natriuretic peptide (NT pro BNP), and the kappa and lambda free light chains. An increase in mean LSM was seen in all patients. Pearson correlation analysis showed a statistically significant correlation between LSM and liver volume (r = 0.78, p = 0.007) and kappa chain level (r = 0.65, p = 0.04). Interestingly, LSM did not correlate significantly with SSM (r = 0.45, p = 0.18), liver span (r = 0.57, p = 0.08), or serum ALP (r = 0.60, p = 0.07). However, LSM correlated significantly with serum ALP when corrected for liver volume (partial correlation, r = 0.71, p = 0.03) and NT pro BNP levels (partial correlation, r = 0.68, p = 0.04). MRI review revealed that amyloid deposition in the liver can be diffuse, lobar, or focal. MRE is useful for the evaluation of hepatic amyloidosis and shows increased stiffness in hepatic amyloidosis. MRE has the potential to be a non-invasive quantitative imaging marker for hepatic amyloidosis.
Intellectual Equipoise and Challenges: Accruing Patients With Advanced Cancer to a Trial Randomizing to Surgical or Nonsurgical Management (SWOG S1316)
Deutsch, Gary B. , Deneve, Jeremiah L. , Al-Kasspooles, Mazin F, Nfonsam, Valentine , Gunderson, Camille C., Secord, Angeles Alvarez , Rodgers, Phillip , Hendren, Samantha , Silberfein, Eric J. , Grant, Marcia , Sloan, Jeff A. , Arnold, Kathryn B. , Sloan, Jeff, Sun, Virginia Chih-Yi , Anderson, Garnet L. , Krouse, Robert S.

Mayo Clinic

American Journal of Hospice and Palliative Medicine® | May 24, 2019 | Volume: 37 | Issue: 1 | Pages: 12-18

10.1177/1049909119851471 | PMID 31122027 Get It

Background: Prospective, randomized trials are needed to determine optimal treatment approaches for palliative care problems such as malignant bowel obstruction (MBO). Randomization poses unique issues for such studies, especially with divergent treatment approaches and varying levels of equipoise. We report our experience accruing randomized patients to the Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction (SWOG S1316) study, comparing surgical and nonsurgical management of MBO. Methods: Patients with MBO who were surgical candidates and had treatment equipoise were accrued and offered randomization to surgical or nonsurgical management. Patients choosing nonrandomization were offered prospective observation. Trial details are listed on www.clinicaltrials.gov (NCT #02270450). An accrual algorithm was developed to enhance enrollment. Results: Accrual is ongoing with 176 patients enrolled. Most (89%) patients chose nonrandomization, opting for nonsurgical management. Of 25 sites that have accrued to this study, 6 enrolled patients on the randomization arm. Approximately 59% (20/34) of the randomization accrual goal has been achieved. Patient-related factors and clinician bias have been the most prevalent reasons for lack of randomization. An algorithm was developed from clinician experience to aid randomization. Using principles in this tool, repeated physician conversations discussing treatment options and goals of care, and a supportive team–approach has helped increase accrual. Conclusions: Experience gained from the S1316 study can aid future palliative care trials. Although difficult, it is possible to randomize patients to palliative studies by giving clinicians clear recommendations utilizing an algorithm of conversation, allotment of necessary time to discuss the trial, and encouragement to overcome internal bias.
Recent Developments of Novel Pharmacologic Therapeutics for Prevention of Chemotherapy-Induced Peripheral Neuropathy
Hu, Shuiying , Huang, Kevin M. , Adams, Elizabeth , Loprinzi, Charles L. , Lustberg, Maryam B. , Lustberg, Maryam

Mayo Clinic

Clinical Cancer Research | May 23, 2019 | Volume: 25 | Issue: 21 | Pages: 6295-6301

10.1158/1078-0432.ccr-18-2152 | PMID 31123053 Get It

Abstract Chemotherapy-induced peripheral neuropathy (CIPN) is a common and dose-limiting toxicity, negatively affecting both quality of life and disease outcomes. To date, there is no proven preventative strategy for CIPN. Although multiple randomized trials have evaluated a variety of pharmacologic interventions for the treatment of CIPN, only duloxetine has shown clear efficacy in a phase III study. The National Cancer Institute's Symptom Management and Health-Related Quality of Life Steering Committee has identified CIPN as a priority for translational research in cancer care. Promising advances in preclinical research have identified several novel preventative and therapeutic targets, which have the potential to transform the care of patients with this debilitating neurotoxicity. Here, we provide an overarching view of emerging strategies and therapeutic targets that are currently being evaluated in CIPN.
If You Can Look Into the Seeds of Time, and Say Which Grain Will Grow and Which Will Not
Taner, Timuçin , Taner, Timucin , Heimbach, Julie K.

Mayo Clinic

Hepatology | May 23, 2019 | Volume: 70 | Issue: 5 | Pages: 1858-1860

10.1002/hep.30785 | PMID 31121072 Get It

Hanging Up the Gloves
Hilal, Talal , Hilal, Talal

Mayo Clinic

The Oncologist | May 23, 2019 | Volume: 24 | Issue: 10 | Pages: 1403-1404

10.1634/theoncologist.2019-0249 | PMID 31122951 Get It

Despite the availability of cancer treatments, the best decision may be to facilitate quality time at the end of life. Through the story of a boxer diagnosed with anaplastic thyroid cancer, this narrative considers the question of when to stop cancer treatment when the road is coming to an end.
Heart Failure With Preserved Ejection Fraction In Perspective
Shah, Amil M. , Borlaug, Barry A. , Borlaug, Barry A , Shah, Amil , Pfeffer, Marc Alan

Mayo Clinic

Circulation Research | May 23, 2019 | Volume: 124 | Issue: 11 | Pages: 1598-1617

10.1161/circresaha.119.313572 | PMID 31120821 Get It

Approximately half of the patients with signs and symptoms of heart failure have a left ventricular ejection fraction that is not markedly abnormal. Despite the historically initial surprise, heightened risks for heart failure specific major adverse events occur across the broad range of ejection fraction, including normal. The recognition of the magnitude of the problem of heart failure with preserved ejection fraction in the past 20 years has spurred an explosion of clinical investigation and growing intensity of informative outcome trials. This article addresses the historic development of this component of the heart failure syndrome, including the epidemiology, pathophysiology, and existing and planned therapeutic studies. Looking forward, more specific phenotyping and even genotyping of subpopulations should lead to improvements in outcomes from future trials.